 Based on the FDAs written comments, United Therapeutics Corporation NASDAQ: UTHR has decided to discontinue the development of Trevyent. Trevyent is a drug-device combination product that combines two-day, single-use, disposable PatchPump technology with treprostinil for the subcutaneous treatment of pulmonary arterial hypertension. 